Vitamin D3 supplement for people with multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This early-phase study tests whether taking a Vitamin D3 supplement can be safe and helpful for people with symptomatic multiple myeloma. It may help researchers understand how Vitamin D affects the disease and how patients tolerate treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have symptomatic multiple myeloma and measurable disease (not smoldering only)
- Be well enough to do usual activities (ECOG/Zubrod score of 0–2)
- Be able to take and swallow oral capsules, and follow study rules
- Be willing to take blood-thinner (DVT) prevention and follow lenalidomide safety rules (REMS)
- If you can become pregnant, you must use required birth-control steps and complete pregnancy tests; if you’re male, use a latex condom with a partner who can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This study tests if a plant-based diet can help people with newly diagnosed multiple myeloma who are receiving a standard 4-cycle drug combination (DRVd). Researchers want to see if changing what you eat might improve treatment results.
This trial tests a personalized approach to maintenance therapy for people with multiple myeloma who have already had a stem cell transplant. Your treatment plan may be adjusted based on how well your cancer responds and on certain risk factors, with the goal of keeping you in remission longer.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This trial tests a new way to give lenalidomide (Revlimid) as a continuous shot under the skin (subcutaneous infusion) for people with multiple myeloma that has come back or not responded after at least one prior treatment. The goal is to see if this method works better and is easier to tolerate than the standard pill form.
This study tests a combination of three cancer drugs (belantamab mafodotin, bortezomib, and dexamethasone) in people with multiple myeloma who have had prior treatment and moderate liver function problems. The goal is to see if this combination works safely in patients whose cancer has come back or worsened.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.